Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)

ClinicalTrials.gov ID: NCT02976038

Public ClinicalTrials.gov record NCT02976038. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-Label Phase 2 Extension Trial to Characterize the Long-term Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2 Open-Label extension study to evaluate the long term safety and tolerability of daily elamipretide injections in patients with genetically confirmed Primary Mitochondrial Disease who previously participated in the SPIMM-202 Clinical Trial

Study identification

NCT ID: NCT02976038
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Enrollment: 28 participants

Conditions and interventions

Conditions

Primary Mitochondrial Disease

Interventions

elamipretide Drug

Drug

Eligibility (public fields only)

Age range: 16 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2016 (Actual)
Primary completion: Mar 9, 2020 (Actual)
Completion: Apr 9, 2020 (Actual)
Last update posted: Dec 17, 2021

2016 – 2020

United States locations

U.S. sites: 4
U.S. states: 4
U.S. cities: 4

Facility	City	State	ZIP	Site status
University of California	San Diego	California	92123	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Akron Children's Hospital	Akron	Ohio	44308	—
Children's Hospital of Pittsburgh of UPMC	Pittsburgh	Pennsylvania	15224	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02976038, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 17, 2021 · Synced Oct 22, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02976038 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →